Skip to main content
SpringerLink
Log in
Book cover

Prostacyclin and Its Receptors pp 109–139Cite as

IP-receptors on platelets

  • Chapter

  • 70 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemostas 1997;78: 1–6.

    CAS  Google Scholar 

  2. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemostas 1997;78:611–616.

    CAS  Google Scholar 

  3. Negrescu EV, Grunberg B, Kratzer MA et al. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. Cardiovasc Drugs Ther 1995;9:619–629.

    Article  PubMed  CAS  Google Scholar 

  4. Maclntyre DE. “Platelet prostaglandin receptors.” In Platelets in Biology and Pathology-2, Gordon JL, ed. Elsevier, 1981;211–247.

    Google Scholar 

  5. Seiss W. Molecular mechanisms of platelet activation. Physiol Rev 1989;69:58–178.

    Google Scholar 

  6. Hawiger J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemostas 1995;74:369–372.

    CAS  Google Scholar 

  7. Body SC. Platelet activation and interactions with the microvasculature. J Cardiovasc Pharmacol 1996;27(Suppl 1):S13–25.

    PubMed  CAS  Google Scholar 

  8. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur Heart J 1995; 16(Suppl L):11–15.

    PubMed  CAS  Google Scholar 

  9. Badimon L. Models to study thrombotic disorders. Thromb Haemostas 1997;78:667–671.

    CAS  Google Scholar 

  10. Moncada S, Gryglewski R, Bunting S et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663–665.

    Article  PubMed  CAS  Google Scholar 

  11. Gryglewski RJ, Bunting S, Moncada S et al. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 1976; 12:685–713.

    Article  PubMed  CAS  Google Scholar 

  12. Moncada S, Herman AG, Higgs EA et al. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977;11:323–344.

    Article  PubMed  CAS  Google Scholar 

  13. Higgs EA, Higgs GA, Moncada S et al. Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. Br J Pharmacol 1978;63:535–539.

    PubMed  CAS  Google Scholar 

  14. Hornstra G, Haddeman E, Don JA. Blood platelets do not provide endoperoxides for vascular prostacyclin production. Nature 1979;279:66–68.

    Article  PubMed  CAS  Google Scholar 

  15. Needleman P. Prostacyclin in blood vessel-platelet interactions: perspectives and questions. Nature 1979;279: 14–15.

    Article  PubMed  CAS  Google Scholar 

  16. Trial co-ordinators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2 / prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 1994;89:588–595.

    Google Scholar 

  17. Wu KK, Papp AC, Manner CE et al. Interaction between lymphocytes and platelets in the synthesis of prostacyclin. J Clin Invest 1987;79: 1601–1606.

    PubMed  CAS  Google Scholar 

  18. Gryglewski RJ, Korbut R, Ocetkiewicz A. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 1978;273:765–767.

    Article  PubMed  CAS  Google Scholar 

  19. Moncada S, Korbut R, Bunting S et al. Prostacyclin is a circulating hormone. Nature 1978;273:767–768.

    Article  PubMed  CAS  Google Scholar 

  20. Christ-Hazelhof E, Nugteren DH. Prostacyclin is not a circulating hormone. Prostaglandins 1981;22:739–746.

    Article  PubMed  CAS  Google Scholar 

  21. Lanham JG, Levin MBZ, Gharavi AE et al. Prostacyclin deficiency in a young woman with recurrent thrombosis. Br Med J 1986;292:435–436.

    Article  CAS  Google Scholar 

  22. Nishio S, Matsuura H, Kanai N et al. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988;47:1–10.

    PubMed  CAS  Google Scholar 

  23. Stürzebecher C-S, Losert W. “Effects of iloprost on platelet activation in vitro.” In Prostacyclin and its Stable Analogue Iloprost, Gryglewski RJ, Stock G, eds. Berlin: Springer-Verlag, 1987;39–45.

    Google Scholar 

  24. Moncada S. Biology and therapeutic potential of prostacyclin. Stroke 1983;14: 157–168.

    PubMed  CAS  Google Scholar 

  25. Bavage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. J Biol Chem 1992;267:11300–11306.

    Google Scholar 

  26. Moncada S. Prostacyclin/thromboxane-mediated mechanisms in platelet-vascular wall interactions. Adv Prostaglandin Thromboxane Leukot Res 1985; 15507–512.

    PubMed  CAS  Google Scholar 

  27. Murata T, Ushikubi F, Matsuoka T et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997;388:678–682.

    PubMed  CAS  Google Scholar 

  28. Sinzinger H, Schernthaner G, Kaliman J. Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris. Prostaglandins 1981;22:773–781.

    Article  PubMed  CAS  Google Scholar 

  29. Kahn NN, Mueller HS, Sinha AK. Impaired prostaglandin E1/I2receptor activity of human blood platelets in acute ischemic heart disease. Circ Res 1990;66:932–940.

    PubMed  CAS  Google Scholar 

  30. Manrique RV, Manrique R. “Resistance of platelets to prostacyclin.” In Prostacyclin and its Stable Analogue Iloprost, Gryglewski RJ, Stock G, eds. Berlin: Springer-Verlag, 1987;57–63.

    Google Scholar 

  31. Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996;72:171–191.

    Article  PubMed  CAS  Google Scholar 

  32. Brass LF, Manning DR, Cichowski K et al. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemostas 1997;78:581–589.

    CAS  Google Scholar 

  33. Merritt JE, Hallam TJ, Brown AM et al. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br J Pharmacol 1991;102:251–259.

    PubMed  CAS  Google Scholar 

  34. Siegl AM, Smith JB, Silver MJ et al. Selective binding site for [3H] prostacyclin on platelets. J Clin Invest 1979;63:215–220.

    Article  PubMed  CAS  Google Scholar 

  35. Ito S, Hashimoto H, Negishi M et al. Identification of the prostacyclin receptor by use of [15-3H1] 19-(3-azidophenyl)-20-norisocarbacyclin, anirreversiblespecific photoaffinity label. J Biol Chem 1992;267:20326–20330.

    PubMed  CAS  Google Scholar 

  36. Eggerman TL, Andersen NH, Robertson RP. Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets. J Pharmacol Exp Ther 1986;236:568–573.

    PubMed  CAS  Google Scholar 

  37. Jones RL, Qian Y, Wise H et al. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol 1997;29:525–535.

    Article  PubMed  CAS  Google Scholar 

  38. Hall JM, Strange PG. The use of a prostacyclin analogue, [3H] iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells. Biosci Reports 1984;4:941–948.

    CAS  Google Scholar 

  39. Seiler S, Brassard CL, Arnold AJ et al. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther 1990;255:1021–1026.

    PubMed  CAS  Google Scholar 

  40. Seiler SM, Brassard CL, Federici ME et al. [3-[ 4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl] phenoxy] acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins 1997;53:21–35.

    Article  PubMed  CAS  Google Scholar 

  41. Seiler SM, Brassard CL, Federici ME et al. 2-[ 3-[ 2-(4,5-Dipheny1-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: (1) inhibition of platelet aggregation and mechanism of action. Thromb Res 1994;74:115–123.

    PubMed  CAS  Google Scholar 

  42. Armstrong RA, Jones RL, MacDermot J et al. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol 1986;87: 543–551.

    PubMed  CAS  Google Scholar 

  43. Schillinger E, Prior G. Prostaglandin I2 receptors in a particulate fraction of platelets of various species. Biochem Pharmacol 1980;29:2297–2299.

    Article  PubMed  CAS  Google Scholar 

  44. Armstrong RA, Lawrence RA, Jones RL et al. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors. Br J Pharmacol 1989;97:657–668.

    PubMed  CAS  Google Scholar 

  45. Lombroso M, Nicosia S, Paoletti R et al. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. Prostaglandins 1984;27:321–333.

    Article  PubMed  CAS  Google Scholar 

  46. Kahn NN, Bauman WA, Sinha AK. Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. Proc Natl Acad Sci USA 1996;93:245–249.

    Article  PubMed  CAS  Google Scholar 

  47. Kahn NN, Bauman WA, Sinha AK. Demonstration of a novel circulating anti-prostacyclin receptor antibody. Proc Natl Acad Sci USA 1997;94:8779–8782

    Article  PubMed  CAS  Google Scholar 

  48. Dutta-Roy AK, Kahn NN, Sinha AK. Interaction of receptors for prostaglandin E1/prostacyclin and insulin in human erythrocytes and platelets. Life Sci 1991;49:1129–1139.

    Article  PubMed  CAS  Google Scholar 

  49. Taussig R, Iniguez-Lluhi JA, Gilman AG. Inhibition of adenylyl cyclase by G1α Science 1993;261:218–221.

    PubMed  CAS  Google Scholar 

  50. Hellevuo K, Yoshimura M, Kao M et al. A novel adenylyl cyclase sequence cloned from the human erythroleukemia cell line. Biochem Biophys Res Commun 1993;192:311–318.

    Article  PubMed  CAS  Google Scholar 

  51. Merritt JE, Brown AM, Bund S et al. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor. Br J Pharmacol 1991;102:260–266.

    PubMed  CAS  Google Scholar 

  52. Hecker G, König E, Ney P et al. Potent inhibition of PAF-stimulated human platelets and polymorphonuclear leukocytes by the PGE1 analog OP-1206. Prog Clin Biol Res 1987;247:317–322.

    Google Scholar 

  53. Eigenthaler M, Nolte C, Halbrügge M et al. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Eur J Biochem 1992;205:471–481.

    Article  PubMed  CAS  Google Scholar 

  54. Katsube N, Sakaguchi K, Fujitani B et al. Anti-platelet and anti-thrombotic effect of OP-41483α-CD, a prostacyclin analogue, in experimental animals. Prostaglandins Leukot Essent Fatty Acids 1993;49:795–804.

    Article  PubMed  CAS  Google Scholar 

  55. Whittle BJR, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 1978;16:373–387.

    Article  PubMed  CAS  Google Scholar 

  56. Matthews JS, Jones RL. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol 1993;108:363–369.

    PubMed  CAS  Google Scholar 

  57. Ashby B. Interactions among prostaglandin receptors. Receptor 1994;4:31–42.

    PubMed  CAS  Google Scholar 

  58. Mao G-F, Jin J-G, Bastepe M et al. Prostaglandin E2 both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes. Prostaglandins 1996;52:175–185.

    Article  PubMed  CAS  Google Scholar 

  59. Nishimura T, Yamamoto T, Komuro Y et al. Antiplatelet functions of a stable prostacyclin analog, SM-10906 are exerted by its inhibitory effect on inositol 1,4,5-trisphosphate production and cytosolic Ca++increase in rat platelets stimulated by thrombin. Thromb Res 1995;79:307–317.

    Article  PubMed  CAS  Google Scholar 

  60. Tsai A, Hsu M-J, Vijjeswarapu H et al. Solubilization of prostacyclin membrane receptors from human platelets. J Biol Chem 1989;264:61–67.

    PubMed  CAS  Google Scholar 

  61. Wise H, Kobayashi T, Hong LL et al. Modification of the carboxyl-terminal tail of the prostacyclin (IP)-receptor increases the efficacy of the IP-receptor partial agonist, BMY 45778. Proc 1 st IUPHAR Conference 1998;p28.

    Google Scholar 

  62. Meanwell NA, Rosenfeld MJ, Trehan AK et al. Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives. J Med Chem 1992;35:3483–3497.

    PubMed  CAS  Google Scholar 

  63. Meanwell NA, Romine JL, Rosenfeld MJ et al. Non-prostanoid prostacyclin mimetics. 5. Structure-activity-relationships associated with[3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl] phenoxy] acetic acid. J Med Chem 1993;36:3884–3903.

    PubMed  CAS  Google Scholar 

  64. Nony P, Ffrench P, Girard P et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. Can J Physiol Pharmacol 1996;74:887–893.

    Article  PubMed  CAS  Google Scholar 

  65. Cavallini L, Coassin M, Borean A et al. Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem 1996;271:5545–5551.

    PubMed  CAS  Google Scholar 

  66. Whittle BJR, Moncada S, Mullane K et al. Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. Prostaglandins 1983;25:205–223.

    Article  PubMed  CAS  Google Scholar 

  67. Toda N. Beraprost Sodium. Cardiovasc Drug Rev 1988;6:222–238.

    Google Scholar 

  68. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990;37:671–681.

    PubMed  CAS  Google Scholar 

  69. Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits CAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 1997;323:371–377.

    PubMed  CAS  Google Scholar 

  70. Siess W, Lapetina EG. Prostacyclin inhibits platelet aggregation induced by phorbol ester or Ca2+ionophore at steps distal to activation of protein kinase C and Ca2+-dependent protein kinases. Biochem J 1989;258:57–65.

    PubMed  CAS  Google Scholar 

  71. Jorgensen KA, Dyerberg J, Stoffersen E. Prostacyclin (PGI2) and the effect of phosphodiesterase inhibitors on platelet aggregation. Pharmacol Res Commun 1979;11:605–614.

    PubMed  CAS  Google Scholar 

  72. Darius H, Lefer AM, Leprán I et al. In vivo interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725. Br J Pharmacol 1985;84:735–741.

    PubMed  CAS  Google Scholar 

  73. Alt U, Leigh PJ, Wilkins AJ et al. Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br J Clin Pharmacol 1986;22:118–119.

    PubMed  CAS  Google Scholar 

  74. Jaschonek K, Faul C, Schmidt H et al. Desensitization of platelets with iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol 1988;147:187–196.

    Article  PubMed  CAS  Google Scholar 

  75. Edwards RJ, MacDermot J, Wilkins AJ. Prostacyclin analogues reduce ADP-ribosylation of the a-subunit of the regulatory Gs-protein and diminish adenosine (A2) responsiveness of platelets. Br J Pharmacol 1987;90:501–510.

    PubMed  CAS  Google Scholar 

  76. Giovanazzi S, Accomazzo MR, Letari O et al. Internalization and down-regulation of the prostacyclin receptor in human platelets. Biochem J 1997;325:71–77.

    PubMed  CAS  Google Scholar 

  77. Fisch A, Tobusch K, Veit K et al. Prostacyclin receptor desensitization is a reversible phenomenon in human platelets. Circulation 1997;96:756–760.

    PubMed  CAS  Google Scholar 

  78. Murray R, Shipp E, Fitzgerald GA. Prostaglandin endoperoxide/thromboxane A2 receptor desensitization. J Biol Chem 1990;265:21670–21675.

    PubMed  CAS  Google Scholar 

  79. Elalamy I, Sharareh E, Vargaftig BB et al. Signal transduction involved in the platelet adenylate cyclase sensitization associated with PGH2/TxA2 receptor desensitization. Br J Haematol 1997;99:190–196.

    Article  PubMed  CAS  Google Scholar 

  80. Discussion on platelet mechanisms. In Prostacyclin and its Stable Analogue Iloprost. Gryglewski RJ, Stock G, eds. Berlin: Springer-Verlag, 1987;103–112.

    Google Scholar 

  81. Sinzinger H, Silberbauer K, Horsch AK et al. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease — a rebound phenomenom? Prostaglandins 1981;21:49–51.

    Article  PubMed  CAS  Google Scholar 

  82. Darius H, Michael-Hepp J, Meyer J. Platelet prostacyclin receptor desensitization by iloprost but not by the analog taprostene. Thromb Haemostas 1993;69:p1336.

    Google Scholar 

  83. Whittle BJR, Moncada S, Whiting F et al. Carbacyclin — a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins 1980;19:605–627.

    PubMed  CAS  Google Scholar 

  84. MacDermot J, Alt U, Leigh PJ et al. “Desensitization of iloprost or prostacyclin responsiveness”. In Prostacyclin and its Stable Analogue Iloprost, Gryglewski RJ, Stock G, eds. Berlin: Springer-Verlag, 1987;53–56.

    Google Scholar 

  85. Watanabe T, Sunaga S, Togo M et al. Protein kinase C plays a key role in the cross-talk between intracellular signalings via prostanoid receptors in a megakaryoblastic cell line, MEG-01s. Biochim Biophys Acta 1996;1304:161–169.

    PubMed  Google Scholar 

  86. Adachi M, Ryo R, Yoshida A et al. Elevation of intracellular calcium ion by prostaglandin E1 and itsinhibition by protein kinase C in a human megakaryocyte leukemia cell line. Cancer Res 1989;49:3805–3808.

    PubMed  CAS  Google Scholar 

  87. Feoktistov I, Breyer RM, Biaggioni I. Prostanoid receptor with a novel pharmacological profile in human erythroleukemia cells. Biochem Pharmacol 1997;54:917–926.

    Article  PubMed  CAS  Google Scholar 

  88. Turner JT, Camden JM, Kansra S et al. Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL. J Pharmacol Exp Ther 1992;263:708–716.

    PubMed  CAS  Google Scholar 

  89. Watanabe T, Yatomi Y, Sunago S et al. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01 s. Blood 1991;78:2328–2336.

    PubMed  CAS  Google Scholar 

  90. Schwaner I, Seifert R, Schultz G. Receptor-mediated increases in cytosolic Ca2+ in the human erythroleukaemia cell line involve pertussis toxin-sensitive and-insensitive pathways. Biochem J 1992;281:301–307.

    PubMed  CAS  Google Scholar 

  91. Schwaner I, Seifert R, Schultz G. The prostacyclin analogues, cicaprost and iloprost, increase cytosolic Ca2+ concentration in the human erythroleukemia cell line, HEL, via pertussis toxin-insensitive G-proteins. Eicosanoids 1992;5:S10412.

    Google Scholar 

  92. Namba T, Oida H, Sugimoto Y et al. cDNA cloning of a mouse prostacyclin receptor. J Biol Chem 1994;269:9986–9992.

    PubMed  CAS  Google Scholar 

  93. Katsuyama M, Sugimoto Y, Namba T et al. Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett 1994;344:74–78.

    Article  PubMed  CAS  Google Scholar 

  94. Smyth EM, Nestor PV, Fitzgerald GA. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 1996;271:33698–33704.

    Article  PubMed  CAS  Google Scholar 

  95. Brass LF, Woolkalis MJ. Dual regulation ofcyclic AMP formation by thrombin in HEL cells, a leukaemic cell line with megakaryocytic properties. Biochem J 1992;281:73–80.

    PubMed  CAS  Google Scholar 

  96. Sasaki Y, Takahashi T, Tanaka I et al. Expression of prostacyclin receptor in human megakaryocytes. Blood 1997;90:1039–1046.

    PubMed  CAS  Google Scholar 

  97. Murray R, Furci L, Fitzgerald GA. Induction of prostacyclin receptor expression in human erythroleukemia cells. FEBS Lett 1989;255:172–174.

    Article  PubMed  CAS  Google Scholar 

  98. Schafer AI. Antiplatelet therapy. Am J Med 1996;101:199–209.

    Article  PubMed  CAS  Google Scholar 

  99. Clinprost. Drugs Future 1997;22:608–625.

    Google Scholar 

  100. Meggiato C, Padoin E, Ragazzi E et al. Inhibition of platelet activation by MM-706, a stable carbacyclin analog, in the conscious rat. Gen Pharmacol 1997;28:251–255.

    PubMed  CAS  Google Scholar 

  101. Data JL, Molony BA, Meinzinger MM et al. Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3’:5’-cyclic monophosphate levels. Circulation 1981;64:4–12.

    PubMed  CAS  Google Scholar 

  102. Whittle BJR, Moncada S. Platelet actions of stable carbocyclic analogues of prostacyclin. Circulation 1985;72:1219–1225.

    PubMed  CAS  Google Scholar 

  103. Grant SM, Goa KL. Iloprost. Drugs 1992;43:889–924.

    PubMed  CAS  Google Scholar 

  104. Schrör K. Antiplatelet drugs. Drugs 1995;50:7–28.

    PubMed  Google Scholar 

  105. Sagripanti A, Carpi A, Rosaia B et al. Iloprost in the treatment of thrombotic microangiopathy: report of thirteen cases. Biomed Pharmacother 1996;50:350–356.

    PubMed  CAS  Google Scholar 

  106. Konno M, Yoshioka A, Takase T et al. Partial clinical improvement in Up shaw-Schulman syndrome following prostacyclin infusion. Acta Paed Jpn 1995;37:97–100.

    CAS  Google Scholar 

  107. Blackwell GJ, Radomski M, Vargas JR et al. Prostacyclin prolongs viability of washed human platelets. Biochim Biophys Acta 1982;718:60–65.

    PubMed  CAS  Google Scholar 

  108. Banning A, Brewer L, Wendt M et al. Local delivery of platelets with encapsulated iloprost to balloon injured pig carotid arteries: effect on platelet deposition and neointim a formation. Thromb Haemostas 1997;77:190–196.

    CAS  Google Scholar 

  109. Fareed J. Current trends in antithrombotic drug and device development. Sem Thromb Hemostas 1996;22(Suppl1):3–8.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

(2002). IP-receptors on platelets. In: Prostacyclin and Its Receptors. Springer, Boston, MA. https://doi.org/10.1007/0-306-46822-0_5

Download citation

  • DOI: https://doi.org/10.1007/0-306-46822-0_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-46308-2

  • Online ISBN: 978-0-306-46822-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation